| Drug-Target Information | ||||||||
|---|---|---|---|---|---|---|---|---|
| Drug Name | Target Name | Drug Type | Target Type | Source | Drug MeSHID | Interaction Score | Drug Status | Target Action |
| p276-00 | cyclin-dependent kinase 1 | NA | Clinical trial target | TTD , DGIDB | Disruptive Impulse Control and Conduct Disorders[MeSHID:D007174] Malignant lymphoma lymphocytic intermediate differentiation diffuse[MeSHID:D020522] |
1.18 | phase 2 | unknown |
| p276-00 | cyclin-dependent kinase 4 | NA | Successful target | TTD , DGIDB | Disruptive Impulse Control and Conduct Disorders[MeSHID:D007174] Malignant lymphoma lymphocytic intermediate differentiation diffuse[MeSHID:D020522] |
2.05 | phase 2 | unknown |
| p276-00 | cyclin-dependent kinase 9 | NA | Clinical trial target | TTD , DGIDB | Disruptive Impulse Control and Conduct Disorders[MeSHID:D007174] Malignant lymphoma lymphocytic intermediate differentiation diffuse[MeSHID:D020522] |
2.45 | phase 2 | unknown |
| click here to return to the previous page | ||||||||